-
Domestic PD-1 immunotherapy! Tislelizumab (tirelizumab) combined with chemotherapy has a strong therapeutic effect on gastric / esophageal cancer!
Time of Update: 2019-11-26
November 26, 2019 / bioun / -- beigene recently announced the phase II clinical research data of anti-PD-1 antibody tislilizumab (tirelizumab) combined with chemotherapy for gastric / gastroesophageal
-
Immunotherapy for lung cancer! Heat's new T cell activating cell therapy hs-110 combined with opdivo shows strong curative effect!
Time of Update: 2019-11-25
November 25, 2019 news / BIOON / -- heat biology is a biopharmaceutical company dedicated to the development of immunotherapy, aiming to use CD8 + "killer" T cells to activate patients' immune system
-
For the first time in ten years, the combination of OS tecentriq in patients with liver cancer is superior to the first-line standard therapy
Time of Update: 2019-11-25
Recently, Roche announced that the combination therapy of atezolizumab (atezolizumab) and Avastin (bevacizumab) for PD-L1 antibody has achieved positive results in the three-stage test imbrave150 for
-
Melanoma immunotherapy! The combination of bestimer opdivo + yervoy in phase III clinical failed to improve the recurrence free survival of patients with PD-L1 < 1%!
Time of Update: 2019-11-21
November 21, 2019 / BIOON / -- Bristol Myers Squibb (BMS) recently announced one of the common primary endpoints of checkmate-915 in the phase III clinical study of melanoma immunotherapy Checkmate-91
-
First line immunotherapy for head and neck cancer! Two schemes of kestruda were approved by the European Union to treat PD-L1 positive patients
Time of Update: 2019-11-21
November 21, 2019 / BIOON / -- cancer immunotherapy giant Merck& CO) recently announced that the European Commission (EC) has approved two schemes of keytruda (Coretta, common name: pembrolizumab, pab
-
Cell: new research helps identify invasive breast cancer that responds to immunotherapy
Time of Update: 2019-11-20
November 20, 2019 / Biovalley BIOON / - -- the United States Food and Drug Administration (FDA) recently approved the combination of immunotherapy drugs and chemotherapy drugs for the treatment of tri
-
First line treatment does not accord with the transplantation of multiple myeloma! The plan of darzalex + RD is approved by the European Union!
Time of Update: 2019-11-20
November 20, 2019 / Biovalley BIOON / - Johnson & Johnson's Janssen Pharmaceutical recently announced that the European Commission (EC) has approved the darzalex (daratumab) combined with lenalidomide
-
Global innovation! Sansheng pharmaceutical is authorized by the new target of immunotherapy PSGL-1 mAb, reprogramming macrophages to stimulate synergistic antitumor response!
Time of Update: 2019-11-18
November 18, 2019 / BIOON / - sansbio pharmaceutical and Verseau therapeutics announced today that according to the cooperation agreement on the development and commercialization of innovative monoclo
-
International Lung Cancer Day, November 17, 2019
Time of Update: 2019-11-18
November 18, 2019 / BIOON / - -- every November is "international lung cancer concern month", and November 17 is "International Lung Cancer Day" "International lung cancer concern month" is a global i
-
The more kinds of leukocyte antigens in cancer patients, the better immune effect
Time of Update: 2019-11-14
A new study published in Nature Medicine found that the more kinds of leukocyte antigens in cancer patients, the better the effect of immunotherapy In the future, doctors are expected to provide bette
-
First line immunotherapy for melanoma! The total remission rate of BMS / nektar star combination nktr-214 + opdivo is 53%, and the complete remission rate is 34%!
Time of Update: 2019-11-13
November 13, 2019 / bioun / -- nektar therapeutics, a partner of Bristol Myers Squibb (BMS), recently announced at the annual meeting of the society for cancer immunotherapy (SITC) in 2019 that bempeg
-
Immunotherapy for advanced liver cancer! Priority review of Bristol Myers Squibb oy portfolio in the US
Time of Update: 2019-11-13
On November 11, BMS announced that FDA has accepted a supplementary biological product license application (SBLA) submitted by BMS, and awarded the breakthrough drug qualification of opdivo and yevoy
-
Pfizer / Merck bavencio research on maintenance treatment of refractory gastric cancer failed!
Time of Update: 2019-11-13
Immunotumor drugs have little effect on the treatment of gastric cancer Recently, Pfizer and Merck's bavencio failed to succeed in the trials of refractory gastric cancer Bavencio failed to beat two o
-
Scientists apply oncolytic adenovirus programmed by synthetic gene circuit to tumor immunotherapy
Time of Update: 2019-11-13
Recently, Tsinghua University and other researchers published the title of "online adenovirus program by synthetic gene circuit for cancer" on nature communications In this paper, we use the synthetic
-
Immunotherapy for liver cancer! Bristol Myers Squibb opdivo + yervoy combination entered the priority review in the United States for second-line treatment!
Time of Update: 2019-11-12
November 12, 2019 / BIOON / - tumor The US Food and Drug Administration (FDA) has accepted a supplementary biological product license application (SBLA) from opdivo (Chinese trade name: odivo, common
-
Immunotherapy for gastric cancer! Merck / Pfizer bavencio first line maintenance treatment phase III clinical failure, failed to extend the total survival period!
Time of Update: 2019-11-11
November 11, 2019 / BIOON / - Pfizer, a US pharmaceutical giant, and Merck KGaA, a partner, recently announced the top line results of the phase III javenlin gastric 100 study (nct02625610) on the tre
-
Science: glutamine blockers enhance antitumor response and are expected to be used in car-t cell therapy
Time of Update: 2019-11-10
November 10, 2019 / biogaky BIOON / - -- in a new study, researchers from Johns Hopkins University in the United States found that a compound that blocks glutamine metabolism can delay tumor growth, c
-
JEM: selective inhibition of low affinity memory CD8 + T cells by early corticosteroid administration
Time of Update: 2019-11-10
November 10, 2019 / BIOON / - -- in the past decade, immune checkpoint blockade (ICB) has shown significant effectiveness in the treatment of multiple advanced cancers However, ICB treatment is often
-
Science: new research on the culprit of T cell failure in cancer
Time of Update: 2019-11-10
November 10, 2019 news / Biovalley BIOON / - -- although the immunocheckpoint blocking therapy has significantly changed the situation of cancer treatment and has clinical effect in cancer treatment,
-
New generation car cell therapy! Takeda and MD Anderson have reached a strategic cooperation to develop ready to use car NK cell therapy from cord blood!
Time of Update: 2019-11-07
November 7, 2019 / Biovalley BIOON / -- Takeda, a Japanese pharmaceutical giant, and MD Anderson Cancer Center at the University of Texas recently announced that they have reached an exclusive license
